Sign in

CIK 0001677077 · <br>Emerging growth company

Alzamend Neuro, Inc.

Sign in to watch
Ticker
ALZN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Apr 30
Incorporated
DE
Entity type
operating
EIN
811822909
Phone
844-722-6333
Business address
480 PEACHTREE ROAD NE, SECOND FLOOR, SUITE 103, ATLANTA, GA, 30326
  1. 4 Open-market buy 10% owner bought 8,000 shares at $1.91 ($15,290)
  2. 4 Open-market buy 10% owner bought 1,612 shares at $2.10 ($3,377)
  3. 4 Open-market buy 10% owner bought 38,000 shares at an average $2.24 ($84,969)
  4. 8-K Event Regulation FD disclosure
  5. 4 Open-market sale Director sold 20,000 shares at $2.85 ($57,086)
  6. 10-Q Report Quarterly Report
  7. 4 Open-market buy 10% owner bought 22,319 shares at an average $2.05 ($45,782)
  8. 4 Open-market buy 10% owner bought 19,681 shares at an average $1.92 ($37,814)
  9. 4 Open-market buy 10% owner bought 145,000 shares at $2.57 ($373,114)
  10. 4 Derivatives Options or other derivatives
  11. 4 Option exercise 10% owner acquired 100,000 shares (option exercise)
  12. 4 Derivatives Options or other derivatives
  13. 4 Option exercise Director acquired 47,222 shares (option exercise)
  14. 4 Option exercise Director acquired 47,222 shares (option exercise)
  15. 4 Option exercise Director acquired 47,222 shares (option exercise)
  16. 4 Option exercise Director acquired 47,222 shares (option exercise)
  17. 8-K Event Regulation FD disclosure
  18. 4 Open-market buy 10% owner bought 5,000 shares at $2.70 ($13,492)
  19. 4 Option exercise Director acquired 2,778 shares (option exercise)
  20. 4 Option exercise Director acquired 2,778 shares (option exercise)

Page 14 of 20 · 398 filings